Please login to the form below
La Jolla Pharmaceutical
This page shows the latest La Jolla Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.
Tecentriq’s triple negative breast cancer use among key CHMP nods
Extensions for AZ drugs, new approval for La Jolla. Roche’s Tecentriq has gained a recommendation for approval in triple-negative breast cancer from Europe’s CHMP, setting it on track ... Among other positive news was La Jolla Pharmaceutical’s
Latest news
-
La Jolla plans filing on back of blood pressure trial data
US biotech La Jolla Pharmaceutical added 76% to the value of its shares yesterday after it reported data from a phase III trial showing its drug for low blood pressure. ... La Jolla estimates that there are around half a million distributive shock cases
-
News in brief, May 17, 2007
Roche inaugurates biotech production centre in Switzerland. Swiss pharmaceutical company Roche has opened a new biotechnology production centre in Basel. ... New CFO for La Jolla Pharmaceuticals. US pharmaceutical company, La Jolla, has hired Niv E
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
